TGF-β1 and TGF-β2 strongly enhance the secretion of plasminogen activator inhibitor-1 and matrix metalloproteinase-9 of the human prostate cancer cell line PC-3

Regulatory Peptides

Volumn 155, Issue 1-3, 2009, Pages 28-32

  Konrad, Lutz ^a   Scheiber, Jonas A ^a   Schwarz, Lena ^a   Schrader, Andres J ^a   Hofmann, Rainer ^a  

^a Medical Faculty   (Germany)

Author keywords

MMP 2; MMP 9; PAI 1; TGF 1; TGF 2

Indexed keywords

GELATINASE A; GELATINASE B; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN SECRETION; SELF STIMULATION; DRUG EFFECT; MALE; METABOLISM; PROSTATE TUMOR; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTATIC NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

EID: 66049105479     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2009.04.012     Document Type: Article

References (34)

1. Derynck R., Akhurst R.J., and Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 29 (2001) 117-129
2. Bierie B., and Moses H.L. TGF-β and cancer. Cytokine Growth Factor Rev 17 (2006) 29-40
3. Annes J.P., Munger J.S., and Rifkin D.B. Making sense of latent TGFβ activation. J Cell Sci 116 Pt2 (2003) 217-224
4. Hyytiainen M., Penttinen C., and Keski-Oja J. Latent TGF-β binding proteins: extracellular matrix association and roles in TGF-β activation. Crit Rev Clin Lab Sci 41 (2004) 233-264
5. Derynck R., and Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425 (2003) 577-584
6. Danielpour D. Functions and regulation of transforming growth factor-beta (TGF-β) in the prostate. Eur J Cancer 41 (2005) 846-857
7. Shariat S.F., Shalev M., Menesses-Diaz A., Kim I.Y., Kattan M.W., Wheeler T.M., and Slawin K.M. Preoperative plasma levels of transforming growth factor beta1 (TGF-β1) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 19 (2001) 2856-2864
8. Perry K.T., Anthony C.T., Case T., and Steiner M.S. Transforming growth factor beta as a clinical biomarker for prostate cancer. Urology 49 (1997) 151-155
9. Wikstrom P., Stattin P., Franck-Lissbrant I., Damber J.E., and Bergh A. Transforming growth factorβ1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 37 (1998) 19-29
10. Shariat S.F., Menesses-Diaz A., Kim I.Y., Muramoto M., Wheeler T.M., and Slawin K.M. Tissue expression of transforming growth factor-β1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. Urology 63 (2004) 1191-1197
11. Dallas S.L., Zhao S., Cramer S.D., Chen Z., Peehl D.M., and Bonewald L.F. Preferential production of latent transforming growth factor β-2 by primary prostatic epithelial cells and its activation by prostate-specific antigen. J Cell Physiol 202 (2005) 361-370
12. Kusakabe M., Cheong P.L., Nikfar R., McLennan I.S., and Koishi K. The structure of the TGF-beta latency associated peptide region determines the ability of the proprotein convertase furin to cleave TGF-betas. J Cell Biochem 103 (2008) 311-320
13. Dennler S., Itoh S., Vivien D., ten Dijke P., Huet S., and Gauthier J.M. Direct binding of Smad3 and Smad4 to critical TGFβ-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 17 (1998) 3091-3100
14. Song C.Z., Siok T.E., and Gelehrter T.D. Smad4/DPC4 and Smad3 mediate transforming growth factor-β (TGF-β) signaling through direct binding to a novel TGF-β-responsive element in the human plasminogen activator inhibitor-1 promoter. J Biol Chem 273 (1998) 29287-29290
15. Durand M.K., Bodker J.S., Christensen A., Dupont D.M., Hansen M., Jensen J.K., Kjelgaard S., Mathiasen L., Pedersen K.E., Skeldal S., Wind T., and Andreasen P.A. Plasminogen activator inhibitor-1 and tumor growth, invasion, and metastasis. Thromb Haemost 91 (2004) 439-449
16. Usher P.A., Thomsen O.F., Iversen P., Johnsen Mm Brunner N., Hoyer-Hansen G., Andreasen P., Dano K., and Nielsen B.S. Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue. Int J Cancer 113 (2005) 870-880
17. Lyon P.B., See W.A., Xu Y., and Cohen M.B. Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines. Prostate 27 (1995) 179-186
18. Soff G.A., Sanderowitz J., Gately S., Verrusio E., Weiss I., Brem S., and Kwaan H.C. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest 96 (1995) 2593-2600
19. Ludwig T. Local proteolytic activity in tumor cell invasion and metastasis. BioEssays 27 (2005) 1181-1191
20. Yu Q., and Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev 14 (2000) 163-176
21. Cardillo M.R., Di Silverio F., and Gentile V. Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer. Anticancer Res 26 (2006) 973-982
22. Konrad L., Scheiber J.A., Voelck-Badouin E., Keilani M.M., Laible L., Brandt H., Schmidt A., Aumüller G., and Hofmann R. Alternative splicing of TGF-betas and their high-affinity receptors TβRI, TβRII and TβRIII (Betaglycan) reveal new variants in human prostatic cells. BMC Genomics 8 (2007) 318
23. Perry K.T., Anthony C.T., and Steiner M.S. Immunohistochemical localization of TGFβ1, TGFβ2, and TGFβ3 in normal and malignant human prostate. Prostate 33 (1997) 133-140
24. Blanchere M., Saunier E., Mestayer C., Broshuis M., and Mowszowicz I. Alterations of expression and regulation of transforming growth factor β in human cancer prostate cell lines. J Steroid Biochem Mol Biol 82 (2002) 297-304
25. Bang Y.J., Kim S.J., Danielpour D., O'Reilly M.A., Kim K.Y., Myers C.E., and Treppel J.B. Cyclic AMP induces transforming growth factor β2 gene expression and growth arrest in the human androgen-independent prostate carcinoma cell line PC-3. Proc Natl Acad Sci U S A 89 (1992) 3556-3560
26. Muir G.H., Butta A., Shearer R.J., Fisher C., Dearnaley D.P., Flanders K.C., Sporn M.B., and Coletta A.A. Induction of transforming growth factor beta in hormonally treated human prostate cancer. Br J Cancer 69 (1994) 130-134
27. Djonov V., Ball R.K., Graf S., Mottaz A.E., Arnold A.M., Flanders K., Studer U.E., and Merz V.W. Transforming growth factor-β3 is expressed in non-dividing basal epithelial cells in normal human prostate and benign prostatic hyperplasia, and is no longer detectable in prostate carcinoma. Prostate 31 (1997) 103-109
28. Dahiya R., Lee C., Haughney P.C., Chui R., Ho R., and Deng G. Differential gene expression of transforming growth factors alpha and beta, epidermal growth factor, keratinocyte growth factor, and their receptors in fetal and adult human prostatic tissues and cancer cell lines. Urology 48 (1996) 963-970
29. Jones H.E., Eaton C.L., Barrow D., Dutkowski C.M., Gee J.M.W., and Griffiths K. Comparative studies of the mitogenic effects of epidermal growth factor and transforming growth factor-α and the expression of various growth factors in neoplastic and non-neoplastic prostatic cell lines. Prostate 30 (1997) 219-231
30. Van Obberghen-Schilling E., Roche N.S., Flanders K.C., Sporn M.B., and Roberts A.B. Transforming growth factor β1 positively regulates its own expression in normal and transformed cells. J Biol Chem 263 (1988) 7741-7746
31. Kim S.J., Angel P., Lafyatis R., Hattori K., Kim K.Y., Sporn M.B., Karin M., and Roberts A.B. Autoinduction of the transforming growth factor β1 is mediated by the AP-1 complex. Mol Cell Biol 10 (1990) 1492-1497
32. Noma T., Glick A.B., Geiser A.G., O'Reilly M.A., Miller J., Roberts A.B., and Sporn M.B. Molecular cloning and structure of the human transforming growth factor-β2 gene promoter. Growth Factors 4 (1991) 247-255
33. Wilson M.J., Jiang A., Wiehr C., Wang X., Sinha A.A., and Pei D. Limited processing of pro-matrix metalloprotease-2 (gelatinase A) overexpressed by transfection in PC-3 human prostate tumor cells: association with restricted cell surface localization of membrane-type matrix metalloproteinase-1. J Androl 25 (2004) 274-285
34. Nalbandian A., and Djakiew D. The p75(NTR) metastasis suppressor inhibits urokinase plasminogen activator, matrix metalloproteinase-2 and matrix metalloproteinase-9 in PC-3 prostate cancer cells. Clin Exp Metastasis 23 (2006) 107-116